When the physician of the prevention center suspected a risk of HCV or HBV infection or if the transaminase ALT level was above normal, an HCV antibody ... fibrosis was demonstrated on liver ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

mice treated with the monoclonal antibody ALT-100 experienced less liver injury and fibrosis than untreated mice. Those fed a high-fat diet and treated with ALT-100 also had reduced glucose ...

Developed for the treatment of fibrosis in the liver, lungs and kidneys ... Based in Allschwil, Alentis specialises in antibody-drug conjugates (ADCs) and antibodies targeting CLDN1 for oncology ...

In an exciting breakthrough, scientists have identified a brand-new genetic disease called Lyn kinase-associated vasculopathy ...

Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. Derived from the platform, LAE105 is a ...

An antibody called bFKB1 improves liver disease and atherosclerosis in ... pathways and in the inactivation of inflammation and fibrosis in the livers of bFKB1 mice. Using microscopy, the ...

An inflammation-targeting antibody drug may help to improve two unrelated ... Mouse models of NAFLD that were treated with ALT-100 had less liver injury and fibrosis – buildup of scar tissue in the ...

Background: FibroTest and elastography have been validated as biomarkers of liver fibrosis ... with confirmed fibrosis were age, male gender, waist circumference, HCV antibody and alcohol ...